Spondyloarthritis & psoriatic arthritis
Male fertility is preserved following ixekizumab treatment—a real-life pilot study
Authors' conclusion
In our limited-size pilot study on SpA and PsO patients, IXE exposure did not impair male fertility.
Study context
- Population
- Consecutive adult male spondyloarthritis (SpA) and/or psoriasis (PsO) patients eligible for or undergoing ixekizumab (IXE) treatment8 SpA, 2 PsO
- Participants
- 10 patients
- Exposure
- Ixekizumab-treated SpA and/or PsO patients vs healthy donors
- IXEn = Ten
- Outcome
- Sperm parameters after a minimum of 6 months of IXE treatment
- Follow-up
- Minimum of 6 months
Methodological detailspilot, real-world, consecutive enrolment, healthy donor control group, Sperm analysis also before treatment initiation in a subgroup of patients
- Pilot
- Real-world
- Consecutive enrolment
- Healthy donor control group
- Sperm analysis also before treatment initiation in a subgroup of patients
Main finding
As reported in the abstract
Sperm parameters · 6 months of IXE
- All patients had normal sperm parameters
Observational data: associations, not effects.
Further findings
Sperm parameters vs healthy donors
- IXE-treated patients had lower sperm concentrations but higher vitality than controls
Patient with baseline oligozoospermia (SpA and PsO) · follow-up
- Normal parameters at follow-up; successful pregnancy post-treatment
- 1
Original publication
Male fertility is preserved following ixekizumab treatment—a real-life pilot study. Rheumatology (Oxford). Published 5 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →